Receptor de la tirosina quinasa

Explorar temas relacionados

Receptor Tyrosine Kinases : Structure, Functions and Role in Human Disease (Reprint) (Paperback)

Receptor Tyrosine Kinases : Structure, Functions and Role in Human Disease (Reprint) (Paperback)

Access : Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas : Modern Pathology

Access : Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas : Modern Pathology

Sunitinib (Sutent) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Sunitinib was the first cancer drug simultaneously approved for two different indications. Sunitinib inhibits cellular signaling by targeting multiple receptor tyrosine kinases (RTKs).  These include all PDGF-Rs and VEGFRs, which play a role in both tumor angiogenesis and tumor cell proliferation.

Sunitinib (Sutent) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Sunitinib was the first cancer drug simultaneously approved for two different indications. Sunitinib inhibits cellular signaling by targeting multiple receptor tyrosine kinases (RTKs). These include all PDGF-Rs and VEGFRs, which play a role in both tumor angiogenesis and tumor cell proliferation.

Regorafenib (BAY 73-4506, commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK).

Regorafenib (BAY 73-4506, commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK).

First complete interactome map of human receptor tyrosine kinases and phosphatases

First complete interactome map of human receptor tyrosine kinases and phosphatases

Quizartinib is an orally available small molecule with potential antineoplastic activity. Class III receptor tyrosine kinase inhibitor AC220 selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis.

Quizartinib is an orally available small molecule with potential antineoplastic activity. Class III receptor tyrosine kinase inhibitor AC220 selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis.

schematic representation of various receptor tyrosine kinase (RTK) sub-types

schematic representation of various receptor tyrosine kinase (RTK) sub-types

AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients: Cancer Cell

AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients: Cancer Cell

DDR1 (discoidin domain receptor tyrosine kinase 1)

DDR1 (discoidin domain receptor tyrosine kinase 1)

Receptor Tyrosine Kinases Part 4 - YouTube

Receptor Tyrosine Kinases Part 4 - YouTube

Pinterest
Buscar